Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bradykinin metabolism is the process by which bradykinin, a potent vasoactive peptide, is synthesized and degraded. Bradykinin is generated from high-molecular-weight kininogen by kallikrein or plasmin. Its short half-life is due to rapid degradation by several enzymes, including angiotensin-converting enzyme (ACE), aminopeptidase P, carboxypeptidases N/M, and neprilysin. ACE is the primary enzyme responsible for bradykinin inactivation. Inhibiting bradykinin metabolism can lead to increased bradykinin levels, potentially causing adverse effects such as angioedema.
N/A
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bradykinin Metabolism (None).